OneSource Specialty Pharma Q1 FY27: 37% revenue, 39% EBITDA

Results at a glance for the June 2026 quarter

OneSource Specialty Pharma Limited (BSE: 544252, NSE: ONESOURCE) reported a strong first quarter of FY27, with higher revenue and profitability compared with the same period last year. The company said performance was supported by the commercial launch of semaglutide, new master service agreement (MSA) contracts, and customer additions across its businesses.

For the quarter ended June 30, 2026 (Q1 FY27), consolidated revenue came in at ₹449.0 crore, up 37% year-on-year (YoY) and 5% quarter-on-quarter (QoQ) from ₹428.2 crore in Q4 FY26. EBITDA rose to ₹123.3 crore, up 39% YoY and 34% QoQ.

The company announced the results on July 24, 2026.

Semaglutide launch and customer wins cited as key drivers

Management linked the quarter’s growth to the commercial launch of semaglutide and a better product mix. It also highlighted new MSA contracts and customer additions as contributors to revenue momentum across business lines.

The company’s narrative suggests it is moving further into commercial revenue streams, following earlier commentary around transitioning from pre-approval to commercial revenues in its DDC portfolio. Separately, earlier disclosures also referenced expectations of significant commercial supplies of semaglutide in the second half, subject to customer approvals.

Alongside GLP-1 related traction, OneSource reported continued commercial activity, including securing six new contracts and receiving 25 requests for proposals (RFPs) across offerings.

Margin recovery: operating leverage shows up in Q1 FY27

EBITDA margin improved to 27.5% in Q1 FY27, compared with 27.0% in Q1 FY26 and 21.5% in Q4 FY26. The company attributed the improvement to operating leverage from higher semaglutide revenues.

The quarter’s profitability progression is notable because the margin change is largely explained through mix and scale, rather than a single one-off item. The company also reported that adjusted metrics exclude exceptional items and scheme-related intangible amortisation, which helps investors compare performance across quarters.

In a separate “quick details” snapshot, an EBITDA margin of 26.51% was also cited for the quarter, alongside headline revenue growth.

Adjusted PAT and EPS: sharp YoY jump

Adjusted Profit After Tax (PAT) for Q1 FY27 stood at ₹63.7 crore, up 72% YoY and 63% QoQ. Adjusted EPS was ₹5.6, compared with ₹3.2 in Q1 FY26 and ₹3.4 in Q4 FY26.

The company clarified that adjusted PAT and adjusted EPS exclude exceptional items and scheme-related intangible amortisation of ₹34.4 crore in each quarter. Exceptional items were reported at ₹4.3 crore in Q1 FY27, compared with a gain of ₹0.03 crore in Q4 FY26 and ₹2.5 crore in Q1 FY26.

Separately, another earnings disclosure for the same quarter reported net income of ₹25.0 crore versus a net loss of about ₹0.19 crore a year earlier. It also reported basic and diluted EPS from continuing operations at ₹2.18.

Consolidated and standalone snapshots show different signals

Standalone profitability was also highlighted in market commentary. OneSource’s standalone net profit for Q1 FY27 was reported at ₹51.2 crore, compared with ₹24.8 crore in Q1 FY26, implying roughly 106% YoY growth.

At the consolidated level, commentary noted that PAT turned profitable versus the year-ago quarter. At the same time, the same commentary flagged that subsidiary losses and a large contingent liability remain areas that investors may monitor alongside headline growth.

Stock and market snapshot around the results

In recent trading around the update, OneSource shares were little changed at ₹1,653.9, down 0.02% from the previous close of ₹1,654.3.

A “quick details” snapshot also listed a market capitalisation of ₹18,967 crore and a current market price (CMP) of ₹1,653.90. Another snapshot listed market cap at ₹19,452.21 crore and CMP at ₹1,693.9, indicating differing reference points in market data cited across notes.

Balance sheet metrics and litigation overhang mentioned

OneSource’s net debt was cited at ₹1,240.6 crore (latest quarter), with total borrowings increasing 46% to ₹1,276 crore.

A separate point highlighted a contingent liability of US$136.32 million tied to Prestige litigation, describing it as an overhang. The company’s longer-term commentary has also referenced a target to keep debt-to-EBITDA below 1.5.

FY28 guidance reiterated: US$100 million organic revenue target

OneSource reaffirmed its FY28 guidance, targeting US$100 million in organic revenue with an EBITDA margin of 40%. The company presented this as a reflection of confidence in long-term growth strategy and expanding manufacturing capabilities.

Earlier commentary also referred to evaluation of potential related-party inorganic transactions, including acquisitions of facilities in Poland and Baroda, described as US FDA-approved and aimed at expanding global footprint.

Partnerships, inspections, and capacity expansion updates

The company has referenced a strategic partnership with Xbrane in biologics, intended to strengthen the drug substance business and support regulatory inspection readiness. Tech transfer for ranibizumab was noted as underway.

Operationally, OneSource has cited major capacity expansion and successful regulatory inspections by the US FDA and ANVISA. These disclosures were positioned as part of broader execution toward scaled commercial supply.

Key financial table (all amounts in ₹ crore)

What the quarter changes for investors

The Q1 FY27 print shows a clear combination of revenue growth and margin improvement, with management explicitly attributing operating leverage to higher semaglutide revenues. The jump in adjusted PAT and the margin rebound from the prior quarter stand out as near-term markers of execution.

At the same time, market commentary around subsidiary performance and the stated contingent liability indicates that investors may continue to separate headline operating momentum from balance-sheet and risk items.

The next set of updates is likely to be watched for confirmation of the semaglutide commercial ramp, the pace of customer and contract additions, and any further clarity on inorganic plans and liabilities.